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Cardiac troponins are regarded as the most specific and
sensitive of the currently available diagnostic techniques
for detection of myocardial damage, and the redefined
criteria used to classify acute coronary syndrome patients
presenting with ischemic symptoms as myocardial infarc-
tion patients are heavily predicated on an increased
concentration of these markers in blood (1 ). Troponins
also are the only markers identifying high-risk coronary
patients who should be treated with antithrombotic
agents, such as glycoprotein IIb/IIIa antagonists, and
referred for invasive evaluation at the earliest opportu-
nity. Not all troponin assays, however, are created equal;
therefore, method selection by the clinical laboratory
represents one of the major factors influencing the perfor-
mance of this important biomarker for the diagnostic
classification of an individual patient. Recent experimen-
tal data indicated that various commercially available
methods have different limits of detection (and impreci-
sion) for cardiac troponins (2 ). Thus, the percentage of
patients recategorized from angina to myocardial infarc-
tion based on troponin results as a diagnostic criterion is
also critically dependent on the performance of the assay
used (3 ).
Formulation of assay reagents is also important in
minimizing analytic interference. Falsely increased or
decreased troponin results may occur because of interfer-
ences with the antigen–antibody reaction. Interferences
from rheumatoid factors or human anti-mouse antibodies,
which can mimic troponin by linking the capture and
detector antibodies, have been reported (4 ). Icteric and
hemolyzed serum samples might also be a problem in
certain immunoassays (5 ). Finally, an interfering blood
component inhibiting the binding of some antibodies
against epitopes in the central part of the cardiac troponin
I (cTnI) molecule has been described (6, 7). The use of
antibodies recognizing these epitopes, which are known
to be less susceptible to proteolysis, has been recom-
mended for the development of cTnI assays (8 ), and many
manufacturers have now endorsed this recommendation.
Thus, the authors of studies on the negatively interfering
factor predicted that many cTnI assays were likely to be
affected by the factor. More and definitive experimental
evidence was, however, required to permit identification
and isolation of this component (9 ).
The first of two studies by Eriksson et al. (10 ) published
in this month’s issue of Clinical Chemistry represents an
important attempt to provide the necessary evidence
about the factor that interferes in the troponin assay.
Using an elegant experimental approach, the authors
identified the factor present in the blood from one indi-
vidual as a circulating troponin autoantibody. Further-
more, they found a correlation, in a small group of
individuals, between the extent of inhibition and the
troponin autoantibody titers estimated with a partially
validated method. Some issues remain undefined, how-
ever, making the entity and the practical importance of
the phenomenon unclear.
The use of serum samples from only one patient for
isolating the interfering factor does not mean that the
previously described, frequently occurring phenomenon
is always and invariably attributable to circulating tropo-
nin autoantibodies. As correctly highlighted by the au-
thors, the high frequency of occurrence of inhibiting factor
is totally unexpected both on the basis of the previously
reported prevalence of similar autoantibodies and from
consideration of the results of the thousands of published
analytical and clinical studies of cardiac troponin assays
(11 ). Only a single case of cTnI autoantibodies causing
false-negative results has been reported previously in the
peer-reviewed literature, and indeed, troponin testing
would never have become the cornerstone for myocardial
infarction diagnosis if there had been false-negative re-
sults in a large proportion of patients (12 ). Furthermore,
the coefficient of determination (r2) obtained from the
relationship between troponin autoantibody titers and
recovery inhibition suggested that the titers explained
only 50% of the inhibition phenomenon, and some of
the individuals in the “normal recovery” group also
appeared to show detectable titers of inhibiting autoanti-
bodies measured with the expressly developed assays
[see Fig. 5 in Eriksson et al. (10 )]. Other causes of the
phenomenon therefore cannot be excluded (9 ). Another
problematic issue was the different saturation potencies of
the autoantibodies presumed to be present in different
individuals with low recovery of added troponin com-
plex. Typically, the presence of inhibiting autoantibodies
in serum leads to false-negative results, such as those
described by Bohner et al. (12 ): it is difficult to explain a
commonly occurring partial inhibition.
To investigate the importance of their results, Eriksson
et al. performed a second study (13 ), in which they
developed a cTnI assay that uses antibodies against
epitopes in both the central and C-terminal parts of the
molecule and thus was unaffected by the presence of
troponin autoantibodies that bind the midmolecule re-
gion. Results from this assay were compared with results
of two other commercial assays that incorporated only
antibodies against the stable midfragment part of cTnI
(13 ). Unfortunately, many factors may influence the pre-
sented results and, at least partially, affect any conclu-
sions. As already said, the sensitivities and imprecision of
assays at low cTnI concentrations may significantly affect
their clinical performance; consequently, it is quite ex-
pected to obtain better results with the new-generation
assay. The assay has substantially improved precision,
detection limit, and sensitivity compared with the corre-
sponding first-generation Innotrac assay, which is based
on the same “all-in-one” (Aio) analytical concept (14, 15).
On the other hand, when a more sensitive cTnI assay, the
Beckman AccuTnI, was used for comparison, the differ-
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ence in clinical performance was attenuated or even
obliterated. Eriksson et al. (13 ) did not provide informa-
tion on the time-dependent clinical sensitivity of AccuTnI,
in comparison with the proposed new assay, for detecting
myocardial infarction early after onset.
Other factors, such as the reactivities of the assays to
various cTnI forms, i.e., the degree of equimolarity, and
the possible influence of EDTA used as anticoagulant for
sample collection in the first part of the study, may also be
important contributors to the differences between the
assays. Eriksson et al. (13 ) reported that the new assay
produced a response to free cTnI that was 40% lower
than that of cTnI in binary complex with troponin C.
Conversely, the same group showed that the antibodies
selected for the first-generation Innotrac Aio assay reacted
equally with free and complexed cTnI, and the same was
shown for the Beckman assay by other authors (16, 17).
We recently reported that the time-dependent difference
observed in the cTnI release kinetics after myocardial
infarction can be explained by the different reactivities of
the compared assays to various cTnI forms, differently
distributed in the early vs late phases of myocardial
infarction (18 ). EDTA splits the calcium-dependent tropo-
nin complexes, thus decreasing concentrations measured
by cTnI assays that preferentially measure these molecu-
lar forms (19 ). A significant interference in the proposed
assay can therefore be supposed, but information related
to this aspect is lacking in the report. On the other hand,
using the first-generation Aio assay, Hedberg et al. (20 )
showed that mean values for EDTA samples were 30%
lower than those for matched heparin samples. Finally, as
reported by Eriksson et al. (13 ), cTnI stability with the
new assay format could be an issue, mainly for the use of
archived samples as happened in their study. It is con-
ceivable that all of these factors can, at least in part,
contribute to the observed differences between the assays.
In agreement with the conclusion of first study by
Eriksson et al. (10 ), clinical and laboratory communities
should be aware that circulating troponin antibodies can
interfere in cTnI assays. Before changing the current
recommendations and alerting users and manufacturers
to revise their scientific beliefs, however, additional spe-
cific and well-designed studies must be performed to
clarify the practical advantages and the impact in the
clinical setting of the proposed analytical changes.
Prof. Panteghini has consulted for and performed studies
supported by the following troponin assay manufactur-
ers: Beckman Coulter, De Mori Innotrac, DiaSorin, Med-
ical Systems, Roche Diagnostics, and Tosoh Bioscience.
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